|
1983
|
|
Founding of Octapharma
|
|
1983
|
|
First commercial application of the SD technology for virus inactivation
|
|
1985
|
|
Octa V.I. low purity FVIII SD virus-inactivated
|
|
1987
|
|
SD virus-inactivated high-purity Factor VIII
|
|
1989
|
|
Acquisition of the Vienna plasma fractionation site
|
|
1991
|
|
World-first SD virus-inactivated, standardised Fresh Frozen Plasma (FFP) for transfusion
|
|
1995
|
|
World-first SD virus-inactivated liquid, ready-to-use immunoglobulin with a two-year shelf-life at room temperature
|
|
1999
|
|
Acquisition of the Lingolsheim plasma fractionation plant
|
|
2002
|
|
Acquisition of Biovitrum's Plasma Business in Sweden
|
|
2003
|
|
Acquisition of Probifasa SA - a Mexican plasma fractionation company
|
|
2003
|
|
Opening of Octapharma subsidiaries in USA and Spain
|
|
2004
|
|
octagam® approved in United States of America
|
|
2004
|
|
First virus-inactivated universally applicable transfusion plasma |
|
2004
|
|
Opening of Octapharma Australia and New Zealand
|
|
2005
|
|
First double virus-inactivated factor VIII / von Willebrand factor concentrate product
|
|
2006
|
|
Acquisition of five donor centers in Germany
|
|
2007
|
|
Opening of first Octapharma donor center in Germany
|
|
2008
|
|
Acquisition of 12 plasmapheresis centers of Life Therapeutics in the USA.
|
|
2008
|
|
Contract signed with International BioResources to develop 33 plasma collection centers across the USA.
|
|
2008
|
|
Opening of Octapharma Italy.
|
|
2008
|
|
Acquisition of fractionation plant in Springe, Germany, from the German Red Cross.
|
|
2009
|
|
Octapharma broke the sales record of Euro 1’000 million. |
|
|
|
|
